Business Wire

GN expands groundbreaking ReSound OMNIA family enabling more people to hear their best in noise

7.2.2023 11:00:00 EET | Business Wire | Press release

Share

GN Hearing, the global leader in hearing aid innovation, today announces the expansion of the popular ReSound OMNIA family, providing more options to address the biggest unmet need for people with hearing loss: hearing speech in noisy environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005021/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

GN expands groundbreaking ReSound OMNIA family enabling more people to hear their best in noise (Photo: Business Wire)

Despite hearing in noise being the main reason why people get hearing aids, 86% of people who wear them still struggle with speech understanding in noise.1 The launch will see GN Hearing expand the premium natural sound offering of ReSound OMNIA into more devices to match the needs and wants of a larger group of people. ReSound OMNIA provides an exceptional 150% improvement in speech understanding in noise2 and is the only hearing solution to simultaneously combine two benefits – narrow beamforming directionality for hearing in noise and omnidirectional listening for a natural listening experience without feeling cut off.2

The ReSound OMNIA technology is available in a full line-up of popular styles to cater to all hearing needs and preferences. In addition to the Receiver-in-Ear hardware launched in August 2022, the family now includes miniRIE, Behind-the-Ear (BTE) and custom-made styles to ensure even more people living with hearing loss will be able to access GN’s most advanced technology, and with greater listening comfort.

As part of the expansion, GN is launching their smallest rechargeable RIE yet, the miniRIE, for a stylish and cosmetic fit without compromising on sound quality. The miniRIE is designed for best wearing comfort, thanks to its size, shape and the soft curves. The device offers all day battery life for worry-free use throughout the day and without the hassle of exchanging fiddly batteries on the go.

GN Hearing CEO and President, Gitte Aabo explains, “Nobody should feel limited by noisy environments. I’m delighted that more people can now benefit from these new best-in-class hearing aids which will help improve hearing in noise without leaving anyone feeling cut off. People with hearing challenges can now strengthen their connections to people and the world around them and hear the sounds that matter.”

All solutions under the ReSound OMNIA family will provide enhanced connectivity, whether users are streaming phone calls or music to their ears. Users can answer calls with just a tap on their hearing aid and enjoy crystal-clear conversations with outstanding sound quality – all without having to take their smart phone out of their pocket.*

The extended ReSound OMNIA portfolio is planned for Regulatory clearance and will be available globally starting with the US and Canada on February 23, 2023, along with the equivalent Beltone Achieve line-up.

For more information, visit the ReSound website.

1 MarkeTrak 22, 2022

2 Jespersen et al (2022)

* ReSound OMNIA hands-free calls are compatible with iPhone 11 or later, iPad Pro 12.9-inch (5th generation), iPad Pro 11-inch (3rd generation), iPad Air (4th generation), and iPad mini (6th generation) or later, with software updates iOS 15.3 and iPadOS 15.3 or later.

- ENDS -

NOTES TO EDITORS

About GN Group

GN Group facilitates communication between people through its intelligent hearing, audio, video, and gaming technology. Inspired by people and driven by our innovation leadership, we leverage technological synergies to deliver unique and increasingly individualized user experiences in our products and solutions.

150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, audio, video and speech, wireless technologies, miniaturization, and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, SteelSeries, Jabra, Beltone, Interton, BlueParrott, Danavox and FalCom in around 100 countries. Founded in 1869, the GN Group employs 7,000 people and is listed on Nasdaq Copenhagen (GN.CO).

Visit our homepage GN.com and connect with us on LinkedIn and Facebook .

© 2023 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad, and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information, please contact:

Press and the media
Aysel Cengiz
Director, Global PR & Communications
Tel: +45 2894 1821

Steen Frentz Laursen
Vice President, Corporate Communications
Tel: +45 45 75 07 21

Investors and analysts
Anne Sofie Staunsbæk Veyhe
Vice President, IR, Treasury and M&A
Tel: +45 45 75 85 06

Rune Sandager
Senior Director, Investor Relations
Tel: +45 45 75 92 57

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 02:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh

Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 22:30:00 EET | Press release

Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati

Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 22:15:00 EET | Press release

Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context

Reply Recognized as a Microsoft Frontier Partner for Enterprise AI Delivery26.3.2026 20:06:00 EET | Press release

Reply [EXM, STAR: REY] announces it has been recognized as a Microsoft Frontier Partner within the Microsoft AI Cloud Partner Program, earning the Frontier Partner Badge for demonstrating advanced capabilities in delivering AI-first solutions across Cloud & AI Platforms, AI Business Solutions, and Security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326965586/en/ The recognition reflects Reply’s capabilities across the Microsoft ecosystem, built through the work of its specialized companies – including Aim Reply, Business Elements Reply, Cluster Reply, Root16 Reply, Solidsoft Reply, Valorem Reply, WM Reply and Zest Reply – supporting enterprise organizations in designing, implementing, and operating AI solutions on Microsoft platforms across real-world business scenarios. The Frontier Partner badge recognizes partners that demonstrate advanced AI driven capabilities and meet rigorous badge requirements at the time of

InterSystems nimittänyt terveydenhuoltotoiminnan johtajaksi tohtori Tim Ferrisin, entisen NHS- ja Mass General ‑johtajan26.3.2026 20:00:00 EET | Tiedote

InterSystems on luovien datateknologiaratkaisujen tarjoaja, jonka ratkaisuihin on tallennettu yli miljardi terveystietotietuetta maailmanlaajuisesti. Yritys ilmoitti tänään nimittäneensä terveydenhuoltotoiminnan johtajaksi lääketieteen tohtori Tim Ferrisin. Nimityksestä ilmoitettiin samaan aikaan, kun terveydenhuoltoalan johtajat kokoontuvat vuoden 2026 HIMSS Global Health Conference & Exhibition ‑tapahtumaan. Roolissaan Ferris pääsee soveltamaan kattavaa toimialakokemustaan, kun hän ohjaa yrityksen terveydenhuoltoratkaisujen kliinistä ja strategista suuntaa maailmanlaajuisesti. Laajan kokemuksensa turvin hän toimii maailmanlaajuisten terveydenhuoltojärjestelmien ja hallitusten strategisena neuvonantajana ja suunnittelee räätälöityjä teknologiaratkaisuja, jotka perustuvat todellisiin johtotason tarpeisiin. Samalla hän edistää akateemista tutkimustaan terveysdata-arkkitehtuurista sekä johtaa julkista keskustelua tekoälyn ja hoidon tarjoamisen yhdistämisestä. Ferris tuo InterSystemsiin a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye